Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells
PDF | HTML | How to cite
Metrics: PDF 1647 views | HTML 2624 views | ?
Liping Han1,2,3,*, Qingwei Zhao3,*, Xianhong Liang3, Xiaoqing Wang4, Zhen Zhang5, Zhiguo Ma3, Miaoqing Zhao6, Aihua Wang2 and Shuai Liu1
1Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China
2Department of Neurology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China
3Department of Neurology, Shandong Police Hospital, Jinan, Shandong, P.R. China
4Department of Pediatric Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China
5Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China
6Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R China
*These authors have contributed equally to this work
Shuai Liu, email: [email protected]
Keywords: glioma, BRD4 inhibition, autophagy, HEXIM1, Akt pathway
Received: March 01, 2017 Accepted: April 03, 2017 Published: April 21, 2017
Inhibition of Brd4 by JQ1 treatment showed potential in the treatment of glioma, however, some cases showed low sensitivity of JQ1. In addition, the pre-clinical analysis showed its limitation by demonstrating that transient treatment with JQ1 leads to aggressive tumor development. Thus, an improved understanding of the mechanisms underlying JQ1 is urgently required to design strategies to improve its efficiency, as well as overcome its limitation. HEXIM1 has been confirmed to have an important role in regulating JQ1 sensitivity. In our study, ubenimex, a classical anti-cancer drug showed potential in regulating the JQ1 sensitivity of glioma cells using the WST-1 proliferation assay. Further studies demonstrated that ubenimex inhibited autophagy and downregulated the autophagic degradation of HEXIM1. The role of HEXIM1 in regulating JQ1 sensitivity was verified by the HEXIM1 knockdown. Since ubenimex was verified as an Akt inhibitor, we further studied the role of Akt inhibition in regulating JQ1 sensitivity and migration of glioma cells. Data showed that ubenimex improved the efficiency of JQ1 treatment and suppressed migration both in the in vitro and in vivo xenografts models. The Akt agonist attenuated these effects, pointing to the role of Akt inhibition in JQ1 sensitivity and suppressed migration. Our findings suggest the potential of ubenimex adjuvant treatment to enhance JQ1 efficiency and attenuate parts of its side effect (enhancing tumor aggressive) by regulating the autophagic degradation of HEXIM1 and Akt inhibition.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.